From: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
Variable | MVD (counts) | Â | VEGF (%) | Â | TSP-1 (%) | Â | ||
---|---|---|---|---|---|---|---|---|
 | Median CD 34 | P value | Low (<4) | High (≥4) | P value | Low (<2) | High (≥2) | P value |
Age | Â | ns | Â | Â | ns | Â | Â | ns |
< 65 | 62 | Â | 20 | 80 | Â | 35 | 27 | Â |
> 65 | 58 | Â | 15 | 85 | Â | 22 | 16 | Â |
Tumor differentiation | Â | ns | Â | Â | ns | Â | Â | ns |
Moderate and well | 55 | Â | 3 | 28 | Â | 12 | 20 | Â |
Poorly and undifferentiated | 59 | Â | 14 | 55 | Â | 32 | 36 | Â |
Clinical subgroups | Â | 0.034 | Â | Â | ns | Â | Â | ns |
More favorable | 46 | Â | 6 | 46 | Â | 28 | 23 | Â |
Unfavorable | 70 | Â | 11 | 37 | Â | 22 | 27 | Â |
Treatment outcome | Â | ns | Â | Â | ns | Â | Â | ns |
Objective response | 58 | Â | 11 | 39 | Â | 22 | 28 | Â |
No response | 59 | Â | 4 | 46 | Â | 25 | 25 | Â |